Investor Sues CBD Pharma Co. Over Clinical Trial Safety Data
CBD drugmaker Zynerba Pharmaceuticals was hit Friday with a shareholder derivative suit claiming the company buried data showing that roughly 20% of participants in a clinical trial for its flagship seizure...To view the full article, register now.
Already a subscriber? Click here to view full article